COVID-19 vaccination enhances the immunogenicity of influenza vaccination

Name: COVID-19 vaccination enhances the immunogenicity of influenza vaccination
Creator: ImmPort
Published: 2025-09-25T00:00:00+08:00

Immunology Database and Analysis Portal2025-10-30 更新2026-07-12 收录

疫苗免疫原性

联合接种临床研究

数据链接：

https://www.immport.org/shared/study/SDY3233 数据链接链接失效反馈

官方服务：

资源简介：

Investigation of the impact of administering both a COVID-19 mRNA vaccine and an influenza virus vaccine in a human cohort study.

提供机构：

ImmPort

创建时间：

2025-09-25

Dynamic trend of neutralizing antibody GMTs (95%CI) for EV71 FCP-As.

疫苗免疫原性

中和抗体动态监测

Female BALB/c mice (4–6 weeks old) were i.p. inoculated with three EV71 FCP-As (V1, V2, and V3) containing 200 U antigen. The sera were isolated and tested at 7, 14, 21, 28, 56 and 84 d post-inoculati

NIAID Data Ecosystem100

Comparison of mouse models of microbial experience reveals differences in microbial diversity and response to vaccination

微生物调控

疫苗动物模型

To better model the human immune experience, the investigators introduce additional microbial experiences to specific pathogen-free mice by way of 3 models.

Immunology Database and Analysis Portal2025-10-30 更新20

Phase I clinical trial dataset: naked DNA SARS-CoV-2 Omicron BA.2 booster vaccine Alveavax-v1.2 against Janssen Ad26.COV2.S comparator, NCT05844202

新冠DNA疫苗I期试验

疫苗免疫原性

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (Alveavax-v1.2): Results of a first-in-human, open-label, active-controlled, randomized dose-finding study of intradermal and subcutaneous applica

NIAID Data Ecosystem00

Modeling in higher dimensions to improve diagnostic testing accuracy: theory and examples for multiplex saliva-based SARS-CoV-2 antibody assays

传染病诊断建模

高维生物统计

To showcase the power of mathematical modeling in diagnostic classification and highlight a method that can be adopted broadly in public health and clinical settings.

DataCite Commons2023-02-20 更新50

Dataset from Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

疫苗免疫原性

疫苗安全性监测

To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore. The vaccine was administered as a single dose to healthy childre

NIAID Data Ecosystem10

COVID-19 vaccination enhances the immunogenicity of influenza vaccination

资源简介：

相关数据集